Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Friday.

Several other analysts have also recently commented on the company. B. Riley restated a “buy” rating and set a $2.30 target price on shares of Cytori Therapeutics in a report on Monday, May 15th. Maxim Group set a $10.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a report on Saturday, May 13th. Finally, Zacks Investment Research upgraded Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $6.45.

Shares of Cytori Therapeutics (NASDAQ CYTX) traded up 0.98% during trading on Friday, hitting $1.03. 302,820 shares of the stock traded hands. The firm’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.45. The company’s market cap is $33.45 million. Cytori Therapeutics has a 52 week low of $0.90 and a 52 week high of $2.48.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.05. Cytori Therapeutics had a negative return on equity of 172.63% and a negative net margin of 314.07%. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $2.32 million. During the same period in the prior year, the company posted ($0.03) earnings per share. The business’s revenue for the quarter was down 53.8% compared to the same quarter last year. On average, equities research analysts anticipate that Cytori Therapeutics will post ($0.90) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “ValuEngine Lowers Cytori Therapeutics Inc (CYTX) to Strong Sell” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/06/04/valuengine-lowers-cytori-therapeutics-inc-cytx-to-strong-sell.html.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. raised its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 19.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 336,651 shares of the biotechnology company’s stock after buying an additional 55,948 shares during the period. Vanguard Group Inc. owned approximately 1.43% of Cytori Therapeutics worth $539,000 as of its most recent SEC filing. Institutional investors own 14.17% of the company’s stock.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.